KR102566496B1 - A pharmaceutical composition for preventing or treating osteoporosis comprising MSM, calcium and rosemary extract as an active ingredient - Google Patents
A pharmaceutical composition for preventing or treating osteoporosis comprising MSM, calcium and rosemary extract as an active ingredient Download PDFInfo
- Publication number
- KR102566496B1 KR102566496B1 KR1020210056276A KR20210056276A KR102566496B1 KR 102566496 B1 KR102566496 B1 KR 102566496B1 KR 1020210056276 A KR1020210056276 A KR 1020210056276A KR 20210056276 A KR20210056276 A KR 20210056276A KR 102566496 B1 KR102566496 B1 KR 102566496B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- rosemary
- calcium
- weight
- preventing
- Prior art date
Links
- 229940092258 rosemary extract Drugs 0.000 title claims abstract description 46
- 235000020748 rosemary extract Nutrition 0.000 title claims abstract description 46
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 title claims abstract description 46
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 239000011575 calcium Substances 0.000 title claims abstract description 38
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 38
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 239000004480 active ingredient Substances 0.000 title claims abstract description 11
- 229960005069 calcium Drugs 0.000 claims abstract description 37
- 229940016409 methylsulfonylmethane Drugs 0.000 claims abstract description 27
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims description 23
- 230000002829 reductive effect Effects 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 11
- 239000008213 purified water Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 241001529742 Rosmarinus Species 0.000 claims 5
- 230000000694 effects Effects 0.000 abstract description 14
- 230000004584 weight gain Effects 0.000 abstract description 6
- 235000019786 weight gain Nutrition 0.000 abstract description 6
- 206010019233 Headaches Diseases 0.000 abstract description 4
- 231100000869 headache Toxicity 0.000 abstract description 4
- 230000007721 medicinal effect Effects 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- 235000001465 calcium Nutrition 0.000 description 32
- 241000241413 Propolis Species 0.000 description 27
- 229940069949 propolis Drugs 0.000 description 27
- 244000178231 Rosmarinus officinalis Species 0.000 description 20
- 210000000988 bone and bone Anatomy 0.000 description 13
- 238000010171 animal model Methods 0.000 description 9
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 8
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 8
- 230000003449 preventive effect Effects 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 238000009806 oophorectomy Methods 0.000 description 7
- 210000002997 osteoclast Anatomy 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102000014128 RANK Ligand Human genes 0.000 description 4
- 108010025832 RANK Ligand Proteins 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 230000037180 bone health Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- -1 etc. may be used Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000008810 intracellular oxidative stress Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000218671 Ephedra Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 101000799321 Lytechinus pictus Actin, cytoskeletal 4 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 235000021127 solid diet Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1578—Calcium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Physical Education & Sports Medicine (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 메틸설포닐메탄, 칼슘 및 로즈마리 추출물을 유효성분으로 포함하는 골다공증 예방 또는 치료용 약학 조성물에 관한 것이다.
본 발명은 쉽고 간단하게 제조할 수 있으며 약효가 우수한 골다공증 예방 또는 치료용 약학 조성물을 제공할 수 있다.
또한 본 발명은 장기간 복용 시 체중 증가, 두통 등의 부작용을 최소화할 수 있는 골다공증 예방 또는 치료용 약학 조성물을 제공할 수 있다.The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis, comprising methylsulfonylmethane, calcium, and rosemary extract as active ingredients.
The present invention can provide a pharmaceutical composition for preventing or treating osteoporosis that can be easily and simply prepared and has excellent medicinal effects.
In addition, the present invention can provide a pharmaceutical composition for preventing or treating osteoporosis that can minimize side effects such as weight gain and headache when taken for a long time.
Description
본 발명은 메틸설포닐메탄, 칼슘 및 로즈마리 추출물을 유효성분으로 포함하는 골다공증 예방 또는 치료용 약학 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis, comprising methylsulfonylmethane, calcium, and rosemary extract as active ingredients.
식물 유래의 다양한 화학물질들은 항 골다공증 작용, 파골세포 분화 억제 작용과 세포보호 작용을 포함한 여러 가지 생리활성들을 나타내어 건강기능식품의 유용한 소재로서 각광을 받고 있다.Various chemical substances derived from plants exhibit various physiological activities including anti-osteoporosis action, osteoclast differentiation inhibitory action, and cytoprotective action, and are in the limelight as useful materials for health functional foods.
한편 국내뿐 아니라 전 세계적으로 고령화, 운동 부족, 흡연 등에 의해 증가하고 있는 골다공증은 다발성 골절, 고관절 골절 등 심각한 위험을 초래하는 질병으로서, 노년기의 삶의 질을 크게 저하시키기 때문에 이를 예방하고 치료하기 위한 생리활성물질의 개발이 요구된다. On the other hand, osteoporosis, which is increasing not only in Korea but also worldwide due to aging, lack of exercise, smoking, etc., is a disease that causes serious risks such as multiple fractures and hip fractures. Development of bioactive substances is required.
이와 관련하여 한국등록특허 제10-1279852호는 하나 이상의 칼슘 보충제 및 하나 이상의 마그네슘 보충제를 포함하는 무기질 혼합물; 및 스트렙토코쿠스 서모필루스 ST3(Streptococcus thermophilus ST3)(KCTC 11870BP); 락토바실루스 람노수스 LR3 (Lactobacillus rhamnosus LR3)(KCTC 11868BP); 및 락토바실루스 파라카제이 LPC4(Lactobacillus paracasei LPC4) (KCTC 11866BP)를 포함하는 골다공증 예방 또는 치료용 조성물을 개시하고 있다.In this regard, Korean Patent Registration No. 10-1279852 discloses a mineral mixture comprising at least one calcium supplement and at least one magnesium supplement; and Streptococcus thermophilus ST3 (KCTC 11870BP); Lactobacillus rhamnosus LR3 (KCTC 11868BP); And a composition for preventing or treating osteoporosis including Lactobacillus paracasei LPC4 (KCTC 11866BP) is disclosed.
또한 한국공개특허 제10-2004-0088976호는 (a) 소뼈, 오징어뼈, 홍조류, 유기산, 및 정제수를 포함하여 구성되는 미네랄 보급용 알칼리 수용액; (b) 생약 조성물; (c) 황태; (d) 검정콩; (e) 표고버섯; (f) casein phospeptide; 및 (g) DHA(Docosahexaenoic acid)를 포함하여 구성되는 골다공증 예방 및 개선용 조성물을 개시하고 있다. In addition, Korean Patent Publication No. 10-2004-0088976 discloses (a) an alkaline aqueous solution for mineral replenishment comprising bovine bones, squid bones, red algae, organic acids, and purified water; (b) a galenic composition; (c) Hwangtae; (d) black beans; (e) shiitake mushrooms; (f) casein phospeptides; and (g) a composition for preventing and improving osteoporosis comprising docosahexaenoic acid (DHA).
아울러 한국공개특허 제10-2012-0001283호는 갈근, 마황, 건강, 대조, 계피, 작약 및 감초를 포함하는 생약 혼합물에 물 또는 유기용매를 가한 후 추출하여 생약 추출물을 제조하고, 상기 생약 추출물에 유산균을 접종하여 발효시킴으로써 제조되는 것을 특징으로 하는 생약 추출물의 유산균 발효물을 유효성분으로 함유하는 골다공증 예방 또는 치료용 약학적 조성물을 개시하고 있다. In addition, Korean Patent Publication No. 10-2012-0001283 discloses that a crude drug extract is prepared by adding water or an organic solvent to a herbal medicine mixture including gal root, ephedra, health, contrast, cinnamon, peony, and licorice, and then extracting the crude drug extract. Disclosed is a pharmaceutical composition for preventing or treating osteoporosis containing, as an active ingredient, a lactic acid bacteria fermentation product of a crude drug extract, which is prepared by inoculating and fermenting lactic acid bacteria.
그러나 상기 문헌에 개시된 기술은 무기질 혼합물, 알칼리 수용액 또는 생약 추출물을 활용한 것으로서, 제조방법이 복잡하고 약효가 우수하지 않다.However, the technology disclosed in the above document utilizes an inorganic mixture, an aqueous alkali solution, or a crude drug extract, and the manufacturing method is complicated and the medicinal effect is not excellent.
또한 장기간 복용 시 체중 증가, 두통, 우울증 등의 부작용을 초래하는 문제점이 있다. In addition, there is a problem that causes side effects such as weight gain, headache, depression, etc. when taken for a long time.
본 발명은 상기 종래 기술의 문제점을 해결하기 위한 것으로서, 쉽고 간단하게 제조할 수 있으며 약효가 우수한 골다공증 예방 또는 치료용 약학 조성물을 제공하는 것을 목적으로 한다. The present invention is to solve the problems of the prior art, and an object of the present invention is to provide a pharmaceutical composition for preventing or treating osteoporosis that can be easily and simply prepared and has excellent medicinal effects.
또한 본 발명은 장기간 복용 시 체중 증가, 두통 등의 부작용을 최소화할 수 있는 골다공증 예방 또는 치료용 약학 조성물을 제공하는데 그 목적이 있다. Another object of the present invention is to provide a pharmaceutical composition for preventing or treating osteoporosis that can minimize side effects such as weight gain and headache when taken for a long time.
상기와 같은 목적을 달성하기 위하여 본 발명은 메틸설포닐메탄, 칼슘 및 로즈마리 추출물을 유효성분으로 포함하는 골다공증 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating osteoporosis comprising methylsulfonylmethane, calcium and rosemary extract as active ingredients.
본 발명의 일실시예에 있어서, 상기 로즈마리 추출물은 로즈마리를 용매로 가열 추출하고 감압 농축하여 수득하는 것을 특징으로 한다.In one embodiment of the present invention, the rosemary extract is characterized in that obtained by heat extraction of rosemary with a solvent and concentration under reduced pressure.
본 발명의 일실시예에 있어서, 상기 로즈마리 추출물은 로즈마리를 용매로 가열 추출하고 감압 농축하여 용매를 제거한 후, 정제수로 수용화한 수용성 추출물인 것을 특징으로 한다.In one embodiment of the present invention, the rosemary extract is characterized in that it is a water-soluble extract obtained by heat-extracting rosemary with a solvent, concentrating under reduced pressure to remove the solvent, and then water-soluble with purified water.
본 발명의 일실시예에 있어서, 상기 조성물은 메틸설포닐메탄 100중량부에 대하여 칼슘 5~30중량부 및 로즈마리 추출물 2~15중량부를 포함하는 것을 특징으로 한다. In one embodiment of the present invention, the composition is characterized in that it comprises 5 to 30 parts by weight of calcium and 2 to 15 parts by weight of rosemary extract based on 100 parts by weight of methylsulfonylmethane.
또한 본 발명은 메틸설포닐메탄, 칼슘 및 로즈마리 추출물을 유효성분으로 포함하는 골다공증 예방 또는 개선용 식품 조성물을 제공한다.In addition, the present invention provides a food composition for preventing or improving osteoporosis comprising methylsulfonylmethane, calcium and rosemary extract as active ingredients.
본 발명은 쉽고 간단하게 제조할 수 있으며 약효가 우수한 골다공증 예방 또는 치료용 약학 조성물을 제공할 수 있다. The present invention can provide a pharmaceutical composition for preventing or treating osteoporosis that can be easily and simply prepared and has excellent medicinal effects.
또한 본 발명은 장기간 복용 시 체중 증가, 두통 등의 부작용을 최소화할 수 있는 골다공증 예방 또는 치료용 약학 조성물을 제공할 수 있다. In addition, the present invention can provide a pharmaceutical composition for preventing or treating osteoporosis that can minimize side effects such as weight gain and headache when taken for a long time.
도 1은 본 발명의 조성물을 섭취한 경우 실험동물의 체중변화를 나타낸다.
도 2는 본 발명의 조성물을 섭취한 경우 실험동물의 대퇴부 뼈의 골밀도를 나타낸다.
도 3은 본 발명의 조성물을 섭취한 경우 실험동물의 대퇴부 뼈의 무기질 함량을 나타낸다. Figure 1 shows the change in body weight of laboratory animals when ingesting the composition of the present invention.
Figure 2 shows the bone density of the femoral bones of experimental animals when ingesting the composition of the present invention.
Figure 3 shows the mineral content of the femoral bones of experimental animals when ingesting the composition of the present invention.
이하 실시예를 바탕으로 본 발명을 상세히 설명한다. 본 발명에 사용된 용어, 실시예 등은 본 발명을 보다 구체적으로 설명하고 통상의 기술자의 이해를 돕기 위하여 예시된 것에 불과할 뿐이며, 본 발명의 권리범위 등이 이에 한정되어 해석되어서는 안 된다.The present invention will be described in detail based on the following examples. The terms, examples, etc. used in the present invention are merely exemplified to explain the present invention in more detail and help the understanding of those skilled in the art, and the scope of the present invention should not be construed as being limited thereto.
본 발명에 사용되는 기술 용어 및 과학 용어는 다른 정의가 없다면 이 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 통상적으로 이해하고 있는 의미를 나타낸다.Technical terms and scientific terms used in the present invention represent meanings commonly understood by those of ordinary skill in the art to which this invention belongs, unless otherwise defined.
본 발명은 메틸설포닐메탄, 칼슘 및 로즈마리 추출물을 유효성분으로 포함하는 골다공증 예방 또는 치료용 약학 조성물에 관한 것이다. The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis, comprising methylsulfonylmethane, calcium, and rosemary extract as active ingredients.
상기 메틸설포닐메탄(Methyl sulfonyl methane; MSM)은 조골세포의 분화를 촉진하여 관절 및 뼈 건강에 도움을 줄 수 있다. The methylsulfonylmethane (Methyl sulfonyl methane; MSM) can promote the differentiation of osteoblasts to help joint and bone health.
상기 칼슘은 골다공증 및 관절질환을 예방하고 개선하는 성분으로서, 해조칼슘, 코랄칼슘, 어골칼슘, 탄산칼슘, 인산칼슘, 난각칼슘, 진주칼슘, 패각칼슘 등이 사용될 수 있으며, 분말, 액상, 이온, 염, 조성물, 복합체 등 다양한 형태로 사용될 수 있다. The calcium is a component that prevents and improves osteoporosis and joint diseases, and seaweed calcium, coral calcium, fish bone calcium, calcium carbonate, calcium phosphate, egg shell calcium, pearl calcium, shell calcium, etc. may be used, and powder, liquid, ionic, It can be used in various forms such as salts, compositions, and complexes.
상기 로즈마리 추출물은 높은 peroxyl radical 소거 활성 및 reducing capacity를 나타내고, 세포 내 산화 스트레스를 효과적으로 감소시켜 우수한 세포 내 항산화 활성을 나타내며, 높은 파골세포 분화 억제 활성을 가지므로 골다공증의 예방에 효과가 있다. The rosemary extract exhibits high peroxyl radical scavenging activity and reducing capacity, effectively reduces intracellular oxidative stress, exhibits excellent intracellular antioxidant activity, and has high osteoclast differentiation inhibitory activity, so it is effective in preventing osteoporosis.
상기 로즈마리 추출물은 로즈마리를 물, 알코올(에탄올, 메탄올, 주정, 발효주정 등), 아세톤 등의 용매로 가열 추출하고 감압 농축하여 수득할 수 있다. The rosemary extract can be obtained by heat-extracting rosemary with a solvent such as water, alcohol (ethanol, methanol, alcohol, fermented alcohol, etc.), acetone, and concentrated under reduced pressure.
예를 들면, 상기 로즈마리 추출물은 로즈마리를 알코올로 가열 추출하고 감압 농축하여 수득한 알코올 추출물인 것이 바람직하다. For example, the rosemary extract is preferably an alcohol extract obtained by heating and extracting rosemary with alcohol and concentrating under reduced pressure.
또한 상기 로즈마리 추출물은 로즈마리를 알코올로 가열 추출하고 감압 농축하여 알코올을 제거한 후, 정제수로 수용화한 수용성 추출물을 사용할 수 있다. In addition, the rosemary extract may use a water-soluble extract obtained by heat-extracting rosemary with alcohol, removing alcohol by concentrating under reduced pressure, and then water-soluble with purified water.
상기 로즈마리 수용성 추출물은 물에 잘 녹고 점도가 낮아 섭취가 간편하고, 상기 수용화 과정을 거치면서 일부 유효성분의 함량이 증가할 수 있다. The rosemary water-soluble extract is easy to ingest because it is well soluble in water and has low viscosity, and the content of some active ingredients may increase through the water-solubilization process.
가열 추출은 로즈마리 100중량부에 대하여 알코올 100~1,000중량부를 가하고 40~90℃에서 1~12시간 가열하여 추출할 수 있으며, 알코올로 1~3시간씩 1~5번 반복해서 가열 추출하는 것이 바람직하다. Heat extraction can be extracted by adding 100 to 1,000 parts by weight of alcohol based on 100 parts by weight of rosemary and heating at 40 to 90 ° C for 1 to 12 hours. do.
가열 추출한 후 감압 농축하여 로즈마리 알코올 추출물을 수득할수 있다. After heat extraction, concentration under reduced pressure can give rosemary alcohol extract.
또한 로즈마리를 알코올로 가열 추출하고 감압 농축하여 알코올을 제거한 후, 이를 다시 정제수로 수용화함으로써, 로즈마리 수용성 추출물을 제조할 수 있다. In addition, a water-soluble extract of rosemary can be prepared by heat-extracting rosemary with alcohol, concentrating under reduced pressure to remove alcohol, and reconstituting it with purified water.
상기 로즈마리 수용성 추출물은 그대로 사용하거나 감압 농축하여 정제수를 제거하여 사용할 수도 있다. The rosemary water-soluble extract may be used as it is or concentrated under reduced pressure to remove purified water.
본 발명은 상기 로즈마리 추출물로서 알코올 추출물과 수용성 추출물을 동시에 사용할 수도 있고, 이때 상기 알코올 추출물 및 수용성 추출물의 중량비는 60~80:20~40 인 것이 바람직하다. 상기 알코올 추출물 및 수용성 추출물의 중량비가 상기 수치범위를 만족하는 경우, 골다공증 예방효과가 극대화될 수 있다. In the present invention, an alcohol extract and a water-soluble extract may be simultaneously used as the rosemary extract, and in this case, the weight ratio of the alcohol extract and the water-soluble extract is preferably 60 to 80:20 to 40. When the weight ratio of the alcohol extract and the water-soluble extract satisfies the above numerical range, the osteoporosis preventive effect can be maximized.
본 발명의 조성물은 메틸설포닐메탄 100중량부에 대하여 칼슘 5~30중량부 및 로즈마리 추출물 2~15중량부를 포함할 수 있다. The composition of the present invention may include 5 to 30 parts by weight of calcium and 2 to 15 parts by weight of rosemary extract based on 100 parts by weight of methylsulfonylmethane.
상기 메틸설포닐메탄, 칼슘 및 로즈마리 추출물의 함량이 상기 수치범위를 만족하는 경우, 골다공증 예방효과가 극대화될 수 있다. When the contents of the methylsulfonylmethane, calcium, and rosemary extract satisfy the above numerical range, the osteoporosis preventive effect can be maximized.
또한 본 발명의 조성물은 프로폴리스 추출물을 추가로 포함할 수 있다. In addition, the composition of the present invention may further include a propolis extract.
상기 프로폴리스 추출물은 높은 peroxyl radical 소거 활성 및 reducing capacity를 나타내고, 세포 내 산화 스트레스를 효과적으로 감소시켜 우수한 세포 내 항산화 활성을 나타내며, 높은 파골세포 분화 억제 활성을 가지므로 골다공증의 예방에 효과가 있다. The propolis extract exhibits high peroxyl radical scavenging activity and reducing capacity, effectively reduces intracellular oxidative stress, exhibits excellent intracellular antioxidant activity, and has high osteoclast differentiation inhibitory activity, so it is effective in preventing osteoporosis.
상기 프로폴리스 추출물은 프로폴리스를 에탄올, 메탄올, 주정, 발효주정 등의 알코올로 가열 추출하고 감압 농축하여 수득한다. The propolis extract is obtained by heating and extracting propolis with an alcohol such as ethanol, methanol, alcohol, fermented alcohol, and the like, and concentrating under reduced pressure.
예를 들면, 상기 프로폴리스 추출물은 프로폴리스를 에탄올로 가열 추출하고 감압 농축하여 수득한 알코올 추출물인 것이 바람직하다. For example, the propolis extract is preferably an alcohol extract obtained by heat-extracting propolis with ethanol and concentrating under reduced pressure.
또한 상기 프로폴리스 추출물은 프로폴리스를 알코올로 가열 추출하고 감압 농축하여 알코올을 제거한 후, 정제수로 수용화한 수용성 추출물을 사용할 수 있다. In addition, as the propolis extract, a water-soluble extract obtained by heat-extracting propolis with alcohol, concentrating under reduced pressure to remove alcohol, and then water-soluble with purified water may be used.
가열 추출은 프로폴리스 100중량부에 대하여 알코올 100~1,000중량부를 가하고 40~90℃에서 1~12시간 가열하여 추출할 수 있으며, 알코올로 1~3시간씩 1~5번 반복해서 가열 추출하는 것이 바람직하다. Heat extraction can be extracted by adding 100 to 1,000 parts by weight of alcohol based on 100 parts by weight of propolis and heating at 40 to 90 ° C for 1 to 12 hours. desirable.
가열 추출한 후 감압 농축하여 프로폴리스 알코올 추출물을 수득한다. Heat extraction and concentration under reduced pressure to obtain a propolis alcohol extract.
또한 프로폴리스를 알코올로 가열 추출하고 감압 농축하여 알코올을 제거한 후, 이를 다시 정제수로 수용화함으로써, 프로폴리스 수용성 추출물을 제조할 수 있다. In addition, a water-soluble extract of propolis can be prepared by heat-extracting propolis with alcohol, concentrating under reduced pressure to remove alcohol, and then soluble in purified water again.
상기 프로폴리스 수용성 추출물은 그대로 사용하거나 감압 농축하여 정제수를 제거하여 사용할 수도 있다. The water-soluble propolis extract may be used as it is or concentrated under reduced pressure to remove purified water.
본 발명은 상기 프로폴리스 추출물로서 알코올 추출물과 수용성 추출물을 동시에 사용할 수도 있고, 이때 상기 알코올 추출물 및 수용성 추출물의 중량비는 20~40:60~80 인 것이 바람직하다. 상기 알코올 추출물 및 수용성 추출물의 중량비가 상기 수치범위를 만족하는 경우, 골다공증 예방효과가 극대화될 수 있다. In the present invention, an alcohol extract and a water-soluble extract may be simultaneously used as the propolis extract, and in this case, the weight ratio of the alcohol extract and the water-soluble extract is preferably 20 to 40:60 to 80. When the weight ratio of the alcohol extract and the water-soluble extract satisfies the above numerical range, the osteoporosis preventive effect can be maximized.
상기 프로폴리스 추출물은 메틸설포닐메탄 100중량부에 대하여 2~10중량부 사용되는 것이 바람직하며, 프로폴리스 추출물의 함량이 상기 수치범위를 만족하는 경우, 골다공증 예방효과가 극대화될 수 있다. The propolis extract is preferably used in an amount of 2 to 10 parts by weight based on 100 parts by weight of methylsulfonylmethane, and when the content of the propolis extract satisfies the above numerical range, the osteoporosis preventive effect can be maximized.
또한 로즈마리 추출물 및 프로폴리스 추출물의 중량비는 60~80:20~40 인 것이 바람직하다. 상기 로즈마리 추출물 및 프로폴리스 추출물의 중량비가 상기 수치범위를 만족하는 경우, 골다공증 예방효과가 극대화될 수 있다. In addition, the weight ratio of the rosemary extract and the propolis extract is preferably 60 to 80:20 to 40. When the weight ratio of the rosemary extract and the propolis extract satisfies the above numerical range, the osteoporosis preventive effect can be maximized.
본 발명의 약학 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical composition of the present invention may further include suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.
상기 담체, 부형제 및 희석제로는 락토즈, 텍스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀롤로즈, 메틸 셀롤로즈, 미정질 셀롤로즈, 폴리비닐 피톨리돈, 물, 메틸히드록시벤조에이트, 프로필 히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.The carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, undecided vaginal cellulose, polyvinyl phytolidone, water, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.
본 발명의 약학 조성물은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions.
또한 본 발명은 메틸설포닐메탄, 칼슘 및 로즈마리 추출물을 유효성분으로 포함하는 골다공증 예방 또는 개선용 식품 조성물에 관한 것이다. In addition, the present invention relates to a food composition for preventing or improving osteoporosis comprising methylsulfonylmethane, calcium and rosemary extract as active ingredients.
식품은 각종 식품류, 캔디, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등의 형태일 수 있고, 분말, 과립, 정제, 캡슐, 음료 등의 형태로 제공될 수 있다. Food may be in the form of various foods, candy, beverages, gum, tea, vitamin complexes, health functional foods, etc., and may be provided in the form of powder, granules, tablets, capsules, beverages, and the like.
이하 실시예를 통해 본 발명을 상세히 설명한다. 하기 실시예는 본 발명의 실시를 위하여 예시된 것일 뿐, 본 발명의 내용이 하기 실시예에 의하여 한정되는 것은 아니다.The present invention will be described in detail through the following examples. The following examples are only exemplified for the practice of the present invention, and the content of the present invention is not limited by the following examples.
(실시예 1) 로즈마리 추출물의 제조(Example 1) Preparation of rosemary extract
건조된 로즈마리 100g 을 95% 에탄올로 50℃에서 3회 환류 추출한 다음 감압 농축하여 추출물을 수득하였다(로즈마리 알코올 추출물).100 g of dried rosemary was refluxed three times at 50° C. with 95% ethanol and then concentrated under reduced pressure to obtain an extract (alcohol extract of rosemary).
건조된 로즈마리 100g 을 95% 에탄올로 50℃에서 3회 환류 추출한 다음 감압 농축하고 용매를 모두 제거한 후, 정제수로 수용화시켜 추출물을 수득하였다(로즈마리 수용성 추출물).100 g of dried rosemary was extracted with 95% ethanol at 50° C. under reflux three times, concentrated under reduced pressure, and all solvents were removed, and then soluble in purified water to obtain an extract (water-soluble rosemary extract).
또한 상기 로즈마리 추출물의 제조방법과 동일한 방법으로 프로폴리스 추출물을 제조하였다.In addition, a propolis extract was prepared in the same manner as the method for preparing the rosemary extract.
(실시예 2) 조성물의 TRAP 활성(Example 2) TRAP activity of composition
Tartrate Resistant Acid Phosphatase(TRAP) 활성은 RAW 264.7 세포를 96-well plate에 1×104 cells/well의 수로 24시간 예비 배양하고, 분화유도배지 [50 ng/mL receptor activator of nuclear factor-κB ligand (RANKL)]와 함께 시료를 농도별로 처리하였다. Tartrate Resistant Acid Phosphatase (TRAP) activity was pre-cultured with RAW 264.7 cells in a 96-well plate at a number of 1×10 4 cells/well for 24 hours, and differentiated induction medium [50 ng/mL receptor activator of nuclear factor-κB ligand ( RANKL)] were treated for each concentration.
매 2일마다 배지 교환 시에 시료를 넣고 총 5일간 배양하였다. Samples were added at the time of medium exchange every 2 days and cultured for a total of 5 days.
Media를 제거한 후 50 μL의 PBS (pH 7.4)로 1회 세척 후 10 mM sodium tartrate와 5mM ρ-nitrophenylphosphate가 포함된 50 mM citrate buffer를 100 μL씩 분주한 후 37℃에서 1시간 반응하였다. After removing the media, washed once with 50 μL of PBS (pH 7.4), dispensed 100 μL of 50 mM citrate buffer containing 10 mM sodium tartrate and 5 mM ρ-nitrophenylphosphate, and reacted at 37℃ for 1 hour.
반응 후 0.1 N NaOH로 반응을 중지시켜 405 nm에서 흡광도를 측정하였다. After the reaction, the reaction was stopped with 0.1 N NaOH, and absorbance was measured at 405 nm.
시료의 RAW 264.7 세포 주에서 파골세포 분화 유도인자인 RANKL에 의해 5일간 분화시킨 후 파골세포 특이적으로 발현되는 Tartrate Resistant Acid Phosphatase (TRAP)의 활성을 측정한 결과는 표 1에 제시된다. Table 1 shows the results of measuring the activity of Tartrate Resistant Acid Phosphatase (TRAP), which is expressed specifically for osteoclasts, after differentiation for 5 days by RANKL, an osteoclast differentiation inducer, in the RAW 264.7 cell line of the sample.
(100:20)Methylsulfonylmethane + Calcium
(100:20)
(100:20:10)Methylsulfonylmethane + Calcium + Rosemary Extract
(100:20:10)
(100:20:1)Methylsulfonylmethane + Calcium + Rosemary Extract
(100:20:1)
(100:20:20)Methylsulfonylmethane + Calcium + Rosemary Extract
(100:20:20)
(100:20:10:5)Methylsulfonylmethane + Calcium + Rosemary Extract + Propolis Extract
(100:20:10:5)
(100:20:5:5)Methylsulfonylmethane + Calcium + Rosemary Extract + Propolis Extract
(100:20:5:5)
(100:20:14:3)Methylsulfonylmethane + Calcium + Rosemary Extract + Propolis Extract
(100:20:14:3)
메틸설포닐메탄, 칼슘 및 로즈마리 추출물을 사용하는 경우 또는 메틸설포닐메탄, 칼슘, 로즈마리 추출물 및 프로폴리스 추출물을 사용하는 경우, RANKL에 의해 유도된 TRAP의 활성을 효과적으로 억제시키는 것으로 나타났다. It was found that the use of methylsulfonylmethane, calcium and rosemary extract or the use of methylsulfonylmethane, calcium, rosemary extract and propolis extract effectively inhibited the activity of TRAP induced by RANKL.
이러한 결과로부터, 로즈마리 추출물 및/또는 프로폴리스 추출물은 파골세포의 형성과 TRAP 활성을 효과적으로 억제시켜 뼈의 흡수를 방해함으로써 뼈 건강에 긍정적 효과를 나타낼 수 있을 것으로 판단된다.From these results, it is believed that the rosemary extract and/or the propolis extract can exhibit a positive effect on bone health by effectively inhibiting the formation of osteoclasts and TRAP activity, thereby interfering with bone resorption.
또한 상기 표에서 알 수 있듯이, 메틸설포닐메탄 100중량부, 칼슘 5~30중량부 및 로즈마리 추출물 2~15중량부를 사용하는 경우, 골다공증 예방효과가 극대화될 수 있다. In addition, as can be seen from the above table, when 100 parts by weight of methylsulfonylmethane, 5 to 30 parts by weight of calcium, and 2 to 15 parts by weight of rosemary extract are used, the osteoporosis preventive effect can be maximized.
아울러 메틸설포닐메탄 100중량부, 칼슘 5~30중량부, 로즈마리 추출물 2~15중량부 및 프로폴리스 추출물 2~10중량부를 사용하는 경우, 골다공증 예방효과가 극대화될 수 있다.In addition, when 100 parts by weight of methylsulfonylmethane, 5 to 30 parts by weight of calcium, 2 to 15 parts by weight of rosemary extract and 2 to 10 parts by weight of propolis extract are used, the osteoporosis preventive effect can be maximized.
또한 로즈마리 추출물 및 프로폴리스 추출물의 중량비가 60~80:20~40 인 경우, 골다공증 예방효과가 극대화될 수 있다. In addition, when the weight ratio of the rosemary extract and the propolis extract is 60 to 80:20 to 40, the osteoporosis preventive effect can be maximized.
(실시예 3) 실험동물의 체중 및 식이효율에 미치는 효과(Example 3) Effect on body weight and dietary efficiency of laboratory animals
난소 절제(ovariectomized)와 가짜수술(sham operation)을 실행한 생후 7주령의 암컷 SD Rat를 (주)중앙실험동물로부터 구입하여 고형식이를 먹이면서 14일간 환경에 적응시킨 후 체중에 따라 총 7군으로 분리하였다 (n=8 per group). 7-week-old female SD rats subjected to ovariectomization and sham operation were purchased from Central Experimental Animals Co., Ltd. and fed solid food to the environment for 14 days. They were separated into groups (n=8 per group).
실험동물에게 고형식이를 10주간 공급하였으며, 양성대조군으로 기제품인 호관원 프리미엄(MSM 25 mg/kg, calcium 4.5 mg/kg)을 선정하였으며, 비교를 위하여 로즈마리 추출물 저농도군(75 mg/kg) 및 고농도군(150 mg/kg)을 선정하였다. A solid diet was supplied to the experimental animals for 10 weeks, and Hogwanwon premium (MSM 25 mg/kg, calcium 4.5 mg/kg), a ready-made product, was selected as a positive control group, and a low-concentration rosemary extract group (75 mg/kg) was used for comparison. and high concentration group (150 mg/kg) were selected.
최종적으로 MSM/Calcium/Rosemary 추출물을 혼합한 소재를 매일 경구투여로 정해진 양을 12주간 공급하였다. 사육장은 인공조명에 의하여 조명시간을 아침 9시부터 저녁 9시까지 12시간으로 조절하였으며 실내온도 25±3℃, 상대습도 50±10%로 유지하였다. 급수는 정수된 일반 식수를 사용하였고 사료와 급수는 제한하지 않았다. Finally, a mixture of MSM/Calcium/Rosemary extract was supplied in a fixed amount by daily oral administration for 12 weeks. In the breeding farm, the lighting time was adjusted to 12 hours from 9:00 am to 9:00 pm by artificial lighting, and the indoor temperature was maintained at 25 ± 3 ° C and the relative humidity was 50 ± 10%. For water supply, purified general drinking water was used, and feed and water were not restricted.
1군: sham operation (가짜 수술군)Group 1: sham operation (sham operation group)
2군: 난소절제Group 2: ovariectomy
3군: 난소절제 + 호관원 프리미엄 formula (MSM/칼슘)Group 3: Ovariectomy + Hogwanwon premium formula (MSM/calcium)
4군: 난소절제 + 로즈마리 저농도Group 4: ovariectomy + rosemary low concentration
5군: 난소절제 + 로즈마리 고농도Group 5: ovariectomy + high concentration of rosemary
6군: 난소절제 + MSM/칼슘/로즈마리 복합소재 formula (로즈마리 저농도)Group 6: ovariectomy + MSM/calcium/rosemary composite formula (rosemary low concentration)
7군: 난소절제 + MSM/칼슘/로즈마리 복합소재 formula (로즈마리 고농도)Group 7: ovariectomy + MSM/calcium/rosemary composite formula (high concentration of rosemary)
MSM/Calcium/로즈마리 추출물 복합소재가 실험동물의 체중에 미치는 영향은 도 1에 제시된다.The effect of the MSM/Calcium/rosemary extract composite material on the body weight of experimental animals is shown in FIG. 1 .
12주간의 실험기간동안 식이섭취효율은 유의적인 차이가 없었으나, 체중 증가는 1군(Sham)과 2군(OVA)간에 유의적인 차이가 나타났으며, 나머지 투여군에서는 유의적인 차이가 없었다. During the 12-week experimental period, there was no significant difference in food intake efficiency, but there was a significant difference in weight gain between group 1 (Sham) and group 2 (OVA), and there was no significant difference in the other administration groups.
이는 난소절제에 의해 지방 축적률이 증가하여 체중증가가 나타났으며, MSM/Calcium/로즈마리 추출물 복합소재는 독성 및 섭취거부가 없으며 영양대사에 영향을 미치지 않는 것으로 나타났다. It was found that the fat accumulation rate increased due to ovariectomy, resulting in weight gain, and the MSM/Calcium/Rosemary extract composite material was not toxic or rejected, and did not affect nutrient metabolism.
(실시예 4) 실험동물의 신장, 간, 자궁 및 대퇴부 뼈에 미치는 효과(Example 4) Effects on the kidneys, liver, uterus and femur bones of experimental animals
실험이 종료되는 시점(12주)에 실험동물을 희생시켜 신장, 간 및 자궁을 적출하여 분석하였으며, 좌측 및 우측 대퇴부 뼈를 적출하여 -70℃에서 보관하여 분석에 사용하였다. At the end of the experiment (12 weeks), the experimental animals were sacrificed, and the kidneys, liver, and uterus were removed and analyzed, and the left and right femoral bones were removed and stored at -70 ° C for analysis.
대퇴부 뼈의 골밀도(bone mineral density, BMD)와 뼈 무기질 함량(bone mineral content, BMC)은 PIXmus (GE medical systems Lunar, USA)를 이용하여 측정하였다. 대퇴부 뼈 조직의 BMD는 cm2 당 g 단위로 표시하였으며, BMC는 g 단위로 표시하였다.Bone mineral density (BMD) and bone mineral content (BMC) of femoral bones were measured using PIXmus (GE medical systems Lunar, USA). The BMD of femoral bone tissue was expressed in grams per cm 2 , and the BMC was expressed in grams.
본 발명의 조성물이 실험동물의 대퇴부 뼈(BMC, BMD)에 미치는 영향은 도 2 및 3에 제시된다. The effect of the composition of the present invention on the femoral bones (BMC, BMD) of experimental animals is shown in FIGS. 2 and 3 .
대퇴부 뼈의 골밀도와 무기질 함량은 2군(OVA)이 1군(Sham)에 비해 감소하였으며, 5군 및 7군은 2군(OVA)에 비해 골밀도와 무기질 함량이 유의적으로 증가한 것으로 나타났다.Bone density and mineral content of femoral bone decreased in group 2 (OVA) compared to group 1 (Sham), and in groups 5 and 7, bone density and mineral content significantly increased compared to group 2 (OVA).
로즈마리 추출물 및 프로폴리스 추출물은 파골세포의 형성을 효과적으로 억제시켜 뼈의 흡수를 방해함으로써 뼈 건강에 긍정적 효과를 나타낼 수 있을 것으로 판단된다.It is believed that the rosemary extract and the propolis extract can have a positive effect on bone health by effectively inhibiting the formation of osteoclasts and preventing bone resorption.
Claims (5)
상기 조성물은 메틸설포닐메탄 100중량부에 대하여 칼슘 5~30중량부 및 로즈마리 추출물 2~15중량부를 포함하고,
상기 로즈마리 추출물은 로즈마리를 용매로 가열 추출하고 감압 농축하여 수득하며,
상기 가열 추출은 로즈마리 100중량부에 대하여 용매 100~1,000중량부를 가하고 40~90℃에서 1~12시간 가열하여 추출하는 것을 특징으로 하는 골다공증 예방 또는 치료용 약학 조성물.
In the pharmaceutical composition for preventing or treating osteoporosis comprising methylsulfonylmethane, calcium and rosemary extract as active ingredients,
The composition contains 5 to 30 parts by weight of calcium and 2 to 15 parts by weight of rosemary extract based on 100 parts by weight of methylsulfonylmethane,
The rosemary extract is obtained by heat extraction of rosemary with a solvent and concentration under reduced pressure,
The heat extraction is a pharmaceutical composition for preventing or treating osteoporosis, characterized in that 100 to 1,000 parts by weight of a solvent is added to 100 parts by weight of rosemary and extracted by heating at 40 to 90 ° C. for 1 to 12 hours.
상기 로즈마리 추출물은 로즈마리를 용매로 가열 추출하고 감압 농축하여 용매를 제거한 후, 정제수로 수용화한 수용성 추출물인 것을 특징으로 하는 골다공증 예방 또는 치료용 약학 조성물.
According to claim 1,
The rosemary extract is a pharmaceutical composition for preventing or treating osteoporosis, characterized in that the water-soluble extract obtained by heat-extracting rosemary with a solvent, concentrating under reduced pressure to remove the solvent, and then water-soluble with purified water.
상기 조성물은 메틸설포닐메탄 100중량부에 대하여 칼슘 5~30중량부 및 로즈마리 추출물 2~15중량부를 포함하고,
상기 로즈마리 추출물은 로즈마리를 용매로 가열 추출하고 감압 농축하여 수득하며,
상기 가열 추출은 로즈마리 100중량부에 대하여 용매 100~1,000중량부를 가하고 40~90℃에서 1~12시간 가열하여 추출하는 것을 특징으로 하는 골다공증 예방 또는 개선용 식품 조성물.
In the food composition for preventing or improving osteoporosis comprising methylsulfonylmethane, calcium and rosemary extract as active ingredients,
The composition comprises 5 to 30 parts by weight of calcium and 2 to 15 parts by weight of rosemary extract based on 100 parts by weight of methylsulfonylmethane,
The rosemary extract is obtained by heat extraction of rosemary with a solvent and concentration under reduced pressure,
The heat extraction is a food composition for preventing or improving osteoporosis, characterized in that extracting by adding 100 to 1,000 parts by weight of a solvent based on 100 parts by weight of rosemary and heating at 40 to 90 ° C. for 1 to 12 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210056276A KR102566496B1 (en) | 2021-04-30 | 2021-04-30 | A pharmaceutical composition for preventing or treating osteoporosis comprising MSM, calcium and rosemary extract as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210056276A KR102566496B1 (en) | 2021-04-30 | 2021-04-30 | A pharmaceutical composition for preventing or treating osteoporosis comprising MSM, calcium and rosemary extract as an active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220149091A KR20220149091A (en) | 2022-11-08 |
| KR102566496B1 true KR102566496B1 (en) | 2023-08-11 |
Family
ID=84041375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210056276A KR102566496B1 (en) | 2021-04-30 | 2021-04-30 | A pharmaceutical composition for preventing or treating osteoporosis comprising MSM, calcium and rosemary extract as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102566496B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116421666B (en) * | 2023-04-07 | 2024-05-07 | 云南德彩堂生物医药科技有限公司 | Anti-osteoporosis grease composition, and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040088976A (en) | 2003-04-14 | 2004-10-20 | 화성용 | alkaline mineral solution, manufacturing method thereof and food for osteoporosis prevention using the same |
| KR101709281B1 (en) | 2010-06-29 | 2017-02-24 | 한국 한의학 연구원 | Composition for Prevention or Treatment of Osteoporosis Comprising Herbal Extract and Fermentation Product thereof with Lactic acid Bacteria |
| KR101279852B1 (en) | 2011-06-29 | 2013-07-09 | 주식회사 쎌바이오텍 | Composition for preventing or treating osteoporosis comprising multi-species pobiotic mixture |
-
2021
- 2021-04-30 KR KR1020210056276A patent/KR102566496B1/en active IP Right Grant
Non-Patent Citations (3)
| Title |
|---|
| Molecular Medicine Reports, 14, 460-466, 2016.* |
| PLOS ONE, 11(7), e0159891/1-12, 2016.* |
| The Journal of Basic & Applied Zoology, 72, 81-88, 2015.* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220149091A (en) | 2022-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1902722B1 (en) | Agent for elevating adiponectin concentration | |
| EP2271367B1 (en) | Mineral absorption accelerator and iron deficiency anemia improver or food composition | |
| KR102257023B1 (en) | Composition comprising Oenothera biennis extract for preventing, treating or improving muscular atrophy or sarcopenia | |
| WO2020177389A1 (en) | Ergothioneine-containing hericium erinaceus health product formulation and preparation method therefor | |
| KR20140040610A (en) | Leaf of smilax china with aspergillus species, method for preparing the same and use of the same | |
| KR102566496B1 (en) | A pharmaceutical composition for preventing or treating osteoporosis comprising MSM, calcium and rosemary extract as an active ingredient | |
| KR101829637B1 (en) | A composition for improving, preventing and treating digestion dysfunction, leukocyte reduce, bone marrow suppression by side effects after anti-cancer therapy comprising Rhus verniciflua stoke extract | |
| WO2016190566A9 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
| KR101565964B1 (en) | Composition Comprising Water Extracts from Pleurotus eryngii var. ferulea (Pf.). for Treating or Preventing hyperlipidemia | |
| KR102286429B1 (en) | A composition for improving, preventing and treating bone-related disease comprising polysaccharide fraction isolated from Nelumbo nucifera leaf | |
| KR101076223B1 (en) | Composition for treating and preventing obesity or hyperlipidemia comprising fermented oriental herb | |
| KR101444760B1 (en) | A composition for preventing bone metabolism-related diseases and increasing bone function comprising mix extracts of Achyranthes bidentata and Siegesbeckia glabrescens | |
| KR101052501B1 (en) | Composition for the prevention and treatment of bone diseases containing herbal extract as an active ingredient | |
| KR102228685B1 (en) | A pharmaceutical composition for preventing or treating osteoporosis comprising propolis extract as an active ingredient | |
| WO2015122728A1 (en) | Anti-tuberculosis composition for treating and preventing tuberculosis comprising melia azedarach l. extract or lobelia chinensis lour extract and fractions thereof | |
| CN111991521A (en) | Tea buccal tablet for reducing high blood pressure, high blood sugar and high blood lipid and preparation method thereof | |
| KR101399398B1 (en) | Method for manufacturing submerged-state fermented Allium victorialis and Composition for preventing or treating anti-diabetes or anti-diabetic complication containing fermented Allium victorialis | |
| KR101134781B1 (en) | Composition comprising an the extract of Allium fistulosum L. for preventing and treating diabetes mellitus | |
| RU2812611C1 (en) | Compositions of ginsenoside rg3 and ginsenoside rg5 and their pharmaceutical uses, including antitumor effects | |
| WO2023224305A1 (en) | Composition for preventing, ameliorating, or treating arthritis and joint pain comprising lysimachia mauritiana extract as active ingredient | |
| KR102567725B1 (en) | A composition for bone health comprising fermented-benicasa hispida extract | |
| KR102618848B1 (en) | Composition containing the hydrolysate of Laminaria by-product extracts for immuno-stimulating activity | |
| KR20180114395A (en) | A health functional food comprising composite material extract for preventing or treating obesity | |
| KR101353943B1 (en) | Composition comprising fermented Dioscorea opposita Thunb. for preventing and treating a gastrointestinal disorder | |
| KR20230053094A (en) | Method for increasing anti-obesity compounds of fruits of Cudrania tricuspidata and a composition for improving and preventing obesity comprising the increased anti-obesity compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |